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Abstract: Increasing evidence suggests the potential role of extracellular vesicles (EVs) in many lung
diseases. According to their subcellular origin, secretion mechanism, and size, EVs are currently
classified into three subpopulations: exosomes, microvesicles, and apoptotic bodies. Exosomes are
released in most biofluids, including airway fluids, and play a key role in intercellular communication
via the delivery of their cargo (e.g., microRNAs (miRNAs)) to target cell. In a physiological context,
lung exosomes present protective effects against stress signals which allow them to participate in
the maintenance of lung homeostasis. The presence of air pollution alters the composition of lung
exosomes (dysregulation of exosomal miRNAs) and their homeostatic property. Indeed, besides their
potential as diagnostic biomarkers for lung diseases, lung exosomes are functional units capable
of dysregulating numerous pathophysiological processes (including inflammation or fibrosis),
resulting in the promotion of lung disease progression. Here, we review recent studies on the known
and potential role of lung exosomes/exosomal miRNAs, in the maintaining of lung homeostasis
on one hand, and in promoting lung disease progression on the other. We will also discuss using
exosomes as prognostic/diagnostic biomarkers as well as therapeutic tools for lung diseases.
Keywords: exosomes; microRNAs; lung diseases; chronic obstructive pulmonary disease; asthma;
acute lung injury/acute respiratory distress syndrome; idiopathic pulmonary fibrosis; diagnostic
biomarkers; therapeutics
1. Introduction
Lung diseases are among the leading causes of death worldwide. Recently, the forum of
international respiratory societies (FIRS) has reported the global burden of lung diseases [1].
Indeed, chronic obstructive pulmonary disease (COPD) affects 65 million people in the world, and
about 3 million people die from it each year, making it the third leading cause of death worldwide [2,3].
More than 300 million people suffer from asthma [4], and about 4 million people annually die from
acute lower respiratory tract infection [5]. Most lung diseases are due to smoke exposure and the poor
quality of the air. As reported by FIRS, at least 2 billion people are exposed to household air pollution
(toxic smoke of biomass fuel) [1] and 1 billion inhale polluted outdoor air. In addition, 1 billion people
are exposed to tobacco smoke. The inhalation of smoke and unhealthy air (air pollution, allergens,
and microbial pathogens) induces airway injury, which is a major risk factor in the development of
lung diseases.
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In a physiological context, airway epithelium is the first line of defense against environmental
toxin, acting as a physical barrier to prevent the intrusion of pollutant agents or pathogens in the lung.
Furthermore, airway epithelium contributes to lung homeostasis by regulating immune reactions and
controlling tissue remodeling needed for repair after injury [6]. Repeated exposure of lung epithelium
to gaseous pollution induces chronic airway inflammation and aberrant repair processes of lung,
resulting in the development of lung diseases [7,8], such as interstitial lung diseases, COPD, or asthma.
In the past decades, extracellular vesicles (EVs) have emerged as essential actors of intercellular
communication, particularly between epithelial cells and lung microenvironment. In this review, we aim
to summarize current knowledge about the role of EVs, principally exosomes and exosomal microRNAs
(miRNAs), in lung physiology and disease pathogenesis, including COPD, asthma, acute lung
injury/acute respiratory distress syndrome (ALI/ARDS), and idiopathic pulmonary fibrosis (IPF).
We also discuss the clinical development of exosome-based diagnosis and therapies for lung diseases.
2. Exosomes as Essential Actors of Intercellular Communication
2.1. Extracellular Vesicle Classification and Biogenesis
EVs are a heterogeneous population of small vesicles (30 nm to 5 µm) containing a phospholipid
bilayer secreted from most, if not all, cell types [9]. These vesicles contain numerous bioactive molecules
(nucleic acids, proteins, and lipids) which confer their biological activities. Cells can release three main
types of EVs classified according to their sub-cellular origin, secretion mechanism, and size (Table 1):
exosomes (30–150 nm), which are internal vesicles generated within late endosomes/multivesicular
bodies (MVBs) and released to an extracellular environment after fusion of MVBs with the plasma
membrane [10–12]; microvesicles (MVs) (also known as microparticles) are larger in size, 100 nm to
1 µm, and are formed by the outward budding and scission of plasma membrane [13]; and apoptotic
bodies (ABs), the largest subtype of EVs (1–5 µm), which are released from plasma membrane of
apoptotic cells [14,15].
Table 1. Extracellular vesicle (EV) classification.
Characteristics Exosomes MVs ABs
Size (nm) 30–150 100–1000 1000–5000
Morphology Cup–shaped Heterogeneous Heterogeneous
Density (g/mL) 1.13–1.19 Undetermined 1.16–1.28
Origin MVBs Plasma membrane Plasma membrane
Biogenesis Fusion of MVBs withplasma membrane




References [9–12] [9,13,16,17] [9,14,15]
Abbreviations: ABs, apoptotic bodies; MVs, microvesicles; MVBs, multivesicular bodies.
The difficulty of isolating pure populations of each type of EVs should be noted, because their size
and density ranges overlap. Indeed, most exosome isolation protocols do not isolate a pure population
of exosomes, but a mixed population of small EVs. So, it is important to accurately characterize the
isolated population for each study. A major ongoing challenge is to establish methods that will allow
a good isolation of exosomes on one hand, and MVs on the other.
2.2. Exosome Composition and Function
Exosomes were first visualized in reticulocytes of rats [18] and sheep [19] in the mid-1980s.
Initially, these vesicles were described as cellular waste and received little attention. Later, several studies
highlighted the role of exosomes in physiological and pathological contexts, such as tumorigenicity,
immune modulation, cardiovascular diseases, or lung diseases. In 2007, Valadi et al. were the first
to demonstrate that mRNAs and miRNAs can be secreted from either human or mice mast cells
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encapsulated into exosomes and transferred to other mast cells [20]. Following this study, hundreds of
others have reported the modulation of various signaling pathways involved in the development
of lung diseases, including inflammatory and fibrotic pathways, via the transfer of select cargoes
from a donor to a recipient cell. Exosomal cargoes are composed of genetic material (DNA, mRNA,
non-coding RNAs including miRNAs and long non-coding RNA), proteins, and lipids. Exosomes are
highly enriched in tetraspanins, including CD63, CD81, and CD9, which have been widely used as
exosomal markers [21]. In addition, these vesicles present a high number of endosomal markers or
markers of the endosomal sorting complex required for transport (such as tumor susceptibility gene
101 or ALG-2-interacting protein X), which reflects their endosomal origin [22].
Exosomes are constitutively secreted into biological fluids (e.g., bronchoalveolar lavage fluid
(BALF), saliva, sputum, plasma) [23–27] and participate in intercellular communication via the transfer
of their content (e.g., miRNAs) to target cells [28–32]. In a physiological context, exosomes play an
important role in maintaining lung homeostasis. In the presence of airway injury, pulmonary cells
release exosomes enriched with pro-inflammatory and pro-fibrotic-miRNAs which participate in the
progression of lung diseases. In that context, interest in exosomes ranges from their function in the
body to more translational applications, such as their use in diagnostics or therapeutics.
3. Exosomal microRNAs Play a Key Role in Lung Homeostasis
Intercellular communication between bronchial epithelial cells (ECs) and the broad range of
cells that are present in the lung microenvironment is essential to keep the lung functioning properly.
Bronchial EC-derived exosomes are major actors in the maintain of lung homeostasis through
the regulation of inflammation and fibrotic processes. Indeed, Kesimer et al. have shown that
epithelial-derived exosomes participate in innate mucosal defense [33]. These vesicles contain surface
associated mucin (MUC)-1, MUC-4, and MUC-16, which confer them a neutralizing effect on the
human influenza virus. Furthermore, Gupta et al. have shown that the transfer of exosomal cargo
between airway ECs significantly alters the qualitative and quantitative profiles of airway secretions,
including MUC hypersecretion, and the miRNA cargo of exosomes in target cells (including miR-34a/b/c,
miR-449b/c, and miR-223) [34]. This finding indicates that epithelial-derived exosomes may be able to
play an important role in airway biology and epithelial remodeling.
Recent studies highlighted the role of alveolar macrophage-derived exosomes on the modulation
of inflammatory state within the lung. In an elegant study, Bourdonnay et al. have demonstrated that
alveolar macrophage-derived exosomes are able to modulate inflammatory signaling by the transfer
of suppressor of cytokine signaling (SOCS) 1 and 3 in alveolar epithelial cells and the inhibition of
signal transducer and activator of transcription (STAT) activation [35]. The secretion of SOCS-enriched
exosomes into the lung fluid was reduced by cigarette smoke (CS) exposure, diminishing their protective
effect against lung inflammation [35]. An additional study by Ismail et al. revealed that MVs derived
from alveolar macrophages are able to regulate airway inflammation through the transfer of miR-223
to various respiratory cells, including lung epithelial cells and monocytes [36].
Endothelial-derived EVs may also play a benefic role in lung homeostasis. Indeed, Njock el al.
have demonstrated that endothelial-derived EVs are able to suppress monocyte activation by the
delivery of anti-inflammatory miR-10a [28]. The immunomodulatory properties of these vesicles may
protect the lung against inflammation that is responsible of several pulmonary diseases, such as COPD
or ARDS.
Based on the above findings, various cell types from the lung microenvironment participate in
regulation of lung homeostasis via the transfer of anti-inflammatory/anti-fibrotic molecules (including
miRNAs) to target cells (Figure 1).
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Inflammatory airway diseases are airway disorders that are related to the persistent 
inflammatory state of the lung, induced by noxious stimuli exposure (e.g., CS, allergens, infections, 
air pollutants) [37]. These related diseases include, among others, COPD, ARDS, and asthma. The 
pathology of COPD is characterized by airway epithelium injury, parenchymal tissue destruction 
(resulting in emphysema), and disruption of normal repair and defense mechanisms (resulting in 
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as a mediator of myofibroblast differentiation by targeting the von Hippel–Lindau protein/hypoxia-
inducible factor 1α signaling pathway [30]. Downregulation of miR-21 prevented CS-induced airway 
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Figure 1. Lung extracellular vesicles (EVs) participate in the maintenance of lung homeostasis.
(1) In a physiological context, bronchial epithelial cells (EC)-derived exosomes contain mucin (MUC)
protein, which give them a neutralizing effect on human influenza virus and participate in innate
mucosal defense [33,34]. (2) In the alveolar space, alveolar macrophage-derived exosomes are able
to modulate inflammatory signaling by the transfer of suppressor of cytokine signaling (SOCS)
proteins [35] or (3)‘miR-223 in various respiratory cells, including alveolar ECs and monocytes [36].
(4) Endothelial-derived EVs could also participate in lung homeostasis by delivering anti-inflammatory
miR-10a to respiratory cells [28].
4. Impact of Exosomal microRNAs in Lung Diseases
4.1. Chronic Obstructive Pulmonary Disease and Exosomal microRNAs
Inflammatory airway diseases are airway disorders that are related to the persistent inflammatory
state of the lung, induced b noxious timuli exposure (e.g., CS, allergens, inf ctions, air pollutants) [37].
These related diseases include, among others, COPD, ARDS, and asthma. The p thology of COPD is
characterized by airway epithelium injury, parenchymal tissue destruction (resulting in emphysema),
and disruption of normal repair and defense m chanisms (resulting in small irway fibrosis) [38].
R piratory epithelium participates in the development of COPD pathogen sis by secreting several
pro-inflammatory cytokines and chemokines [39,40], which promote a d maintain lung i flammation.
Recent studies have demonstrated the import nce of EVs for promoti g COPD disease by modulating
the epithelial-to-mesenchymal transiti (EMT) process. Inde d, Xu et al. have shown that CS
triggers the modification of the compone ts of bronchial epithelial-derived exosomes and identified
exosomal miR-21 derived from bronchial epithelial c lls as a mediator of my fibr blast differentiation
by targeting th von Hippel–Lin au protein/hypoxia-inducible factor 1α sig aling at w y [30].
Downregulati n of miR-21 prevented CS-induced airway remodeling [30]. Furthermore, t e levels
of exosom l miR-21 were high in sera of sm kers and COPD patients and ar inversely correlated
with Forced Expiratory Volume in one second/Forced Vital Capacity (FEV1/FVC), which highlights
the potential value of exosomal mir-21 for diagnosis and treatment of COPD. Rec ntly, He et al. have
demonstrated that bronchial ECs could generate EVs with less miR-21 when treated with CS extract,
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alleviating the polarization of M2 macrophages, which indirectly modulate the EMT process in the
COPD pathogenesis [41]. Previously, Fujita et al. also observed that CS induced relative upregulation
of miR-210 expression in both bronchial ECs and their corresponding EVs [31]. They demonstrated
that miR-210 could be transferred into lung fibroblasts via bronchial EC-derived EVs and induce
myofibroblast differentiation by silencing the critical autophagy-related factor, ATG7 [31]. This study
indicated that CS exposure induced a modification of the composition of bronchial EC-derived EVs
and identified exosomal miR-210 as a paracrine autophagy mediator of myofibroblast differentiation.
Serban et al. found that CS exposure was sufficient to increase MV levels in plasma of humans and
mice, and in supernatants of primary human lung microvascular endothelial cells [17]. CS exposure
also altered the composition of endothelial MVs, with an enrichment of let-7d, miR-191, miR-126,
and miR-125a [17]. The delivery of those miRNAs to specialized macrophages by endothelial MVs
affects the clearance of apoptotic cells. The authors suggested that these targetable effects may be
important in the pathogenesis of diseases linked to endothelial injury and inflammation in smokers,
such as COPD.
Taken together, all these studies demonstrated that CS exposure induces the alteration of
EVs/exosomes composition (e.g., miRNAs), which, in turn, dysregulates several cellular processes
involved in the progression of COPD diseases, such as EMT/myofibroblast differentiation (Figure 2).
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the delivery of (1) miR-21 [30] and (2) miR-210 [31] to lung fibroblasts. (3) Furthermore, endothelial-
derived EVs are able to inhibit the clearance of apoptotic cells by delivering let-7d, miR-191, miR-126, 
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4.2. Asthma and Exosomal microRNAs 
Asthma is a chronic inflammatory airway disease characterized by airway hyperresponsiveness 
and reversible airway obstruction induced by air pollutants and allergens, and increased expression 
Figure 2. Role of lung EVs in the pathogenesis of Chronic Obstructive Pulmonary Disease (COPD). In the
context of COPD, bronchial ECs-derived EVs are able to induce myofibroblast differentiation by the
delivery of (1) miR-21 [30] and (2) miR-210 [31] to lung fibroblasts. (3) Furthermore, endothelial-derived
EVs are able to inhibit the clearance of apoptotic cells by delivering let-7d, miR-191, miR-126, and
miR-125a in lung macrophages [17].
4.2. Asthma and Exosomal microRNAs
Asthma is a chronic inflammatory airway disease characterized by airway hyperresponsiveness
and reversible airway obstruction induced by air pollutants and allergens, and increased expression of
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pro-inflammatory cytokines (such as interleukin (IL)-4, IL-5, and IL-13), which contribute to infiltrating
inflammatory cells [42,43]. In asthma, several studies have reported an alteration of miRNA expression
in different compartments, including airway biopsies, circulating cells (lymphocytes, neutrophils),
and biofluids (peripheral blood, BALF, and sputum supernatants) [44–46]. For example, Maes et al. have
reported elevated levels of three miRNAs (miR-629-3p, miR-223-3p, and miR-142-3p) in the sputum
of patients with severe asthma compared to healthy subjects [47]. The upregulation of miR-629-3p
in human bronchial ECs induced the expression of pro-inflammatory cytokine IL-8, suggesting that
this miRNA may contribute to neutrophilic asthma inflammatory phenotype. Similarly, the exosomal
miRNA content is also altered in asthmatics [24,32,48]. In a recent study, Pua et al. have shown that
the composition of extracellular miRNAs of BALF of an untreated mouse was highly correlated with
airway-lining epithelium, and found that 80% of detected vesicles were of epithelial origin [32].
After induction of allergic airway inflammation, the levels of EV-derived miRNAs selectively
expressed by immune cells, including miR-223 and miR-142a, increased in BALF from allergen-treated
mice [32]. They showed that infiltrating immune cells alter the local extracellular environment via
the release of EV-derived miRNAs in inflamed tissues. In addition, several miRNAs dysregulated in
asthmatic-derived exosomes are associated with inflammation, which suggests that these exosomal
miRNAs could impact lung inflammation and contribute to asthma progression (Figure 3).
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Figure 3. Role of lung EVs in the pathogenesis of asthma. (1) In the context of asthma, elevated levels
of three sputum microRNAs (miRNAs), miR-629-3p, miR-223-3p, and miR-142-3p, in the sputum of
patients with severe asthma, have been reported [47]. The delivery of miR-629-3p in lung ECs could
participate in lung inflammation (release of pro-inflammatory cytokines, interleukin (IL)-6 and IL-8,
by ECs) [47]. (2) The levels of EV-derived miRNAs selectively expressed by immune cells, including
miR-223 and miR-142a, increased in bronchoalveolar lavage fluid (BALF) from allergen-treated mice [32].
It would be interesting to study the impact of these exosomal miRNAs on lungs.
4.3. Acute Lung Injury/Acute Respiratory Distress Syndrome and Exosomal microRNAs
ALI/ARDS is a devastating respiratory disorder, characterized by increased vascular permeability,
alveolar hemorrhage, and fibrin deposition [49]. Increasing evidence suggests that macrophages are key
factors in the pathogenesis of ALI/ARDS [50]. In ALI/ARDS context, Lee et al. found that acid inhalation
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in mice induces a remarkable release of epithelium-derived MVs detected in BALF enriched with
several miRNAs, including miR-17 and miR-221 [51]. Functional studies revealed that acid-induced
epithelial MV-miR-17/221 promotes macrophage β1 integrin recycling and macrophage migration
in vitro and recruitment into the lung in vivo, and ultimately contributes to lung inflammation [51].
Several studies have shown that hyperoxia stimulates the release of lung epithelial-derived EVs,
which are able to impact the progression of ALI disease [52,53]. For example, Moon et al. have
shown that lung epithelial EVs released in hyperoxia condition are able to activate macrophages
which promotes neutrophil infiltration in ALI [52]. In another study, Lee et al. showed that hyperoxia
up-regulates the levels of certain specific miRNAs in epithelial-derived MVs, including miR-320a and
miR-221 [53]. Functionally, the hyperoxia-induced epithelial MVs promote macrophage activation
in vitro and facilitate the recruitment of immunomodulatory cells in vivo, which demonstrates that
epithelial-derived MVs are able to promote macrophage-regulated lung inflammatory responses via
MV-shuttling miRNAs. In a bacterial pneumonia context, macrophages released a rapid and robust
amount of ABs enriched in a repertoire of miRNAs, including miR-221 and miR-222 [54]. The delivery
of AB-derived miR-221/222 promotes the proliferation of lung ECs by modulating cyclin-dependent
kinase inhibitor 1B pathways [54], which could modulate features of lung diseases. In another study,
Lee et al. have showed that alveolar EC-derived EVs contribute to innate immune responses after
bacterial lung infection [55]. These vesicles actively delivered miRNAs into alveolar macrophages,
subsequently promoting inflammasome activation, neutrophil recruitment, and M1-macrophage
polarization in response to P. aeruginosa pneumonia in vivo.
In conclusion, EVs/exosomes generated in ALI/ARDS context present pro-inflammatory properties
which allow them to activate immune system (e.g., alveolar macrophages) and promote lung
inflammation (Figure 4).
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Figure 4. Role of lung EVs in the pathogenesis of cute Lung Injury/Acute Respiratory Distress
Syndrome (ALI/ARDS) (1–5). In the context of ALI/ARDS, EVs released by bronchial ECs and alveolar
macrophages contribute to lung inflammation. Indeed, these vesicles are able to activate macrophages
and promote the infiltration of immune cells (macrophages, neutrophils) in the lung in a miRNA
transfer-dependent manner (deliv ry of (1) miR-17/miR-221 [51] and (3) miR-320a/miR-221 [53] in
alveolar macroph ges via epith lial EVs) or (2) caspase-3-depende t ma ner [52]. (4) In addition,
the alveolar macrophages-derived EVs are able to promote the proliferation of lung ECs by delivering
miR-221/222 [54]. (5) After bacterial lung infection, alveolar EC-derived EVs contribute to innate immune
responses by delivering miRNAs into alveolar macrophages, subsequently promoting inflammasome
activation, neutrophil recruitment, and M1-macrophage polarization [55].
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4.4. Idiopathic Pulmonary Fibrosis and Exosomal microRNAs
IPF is a progressive fibrosing interstitial lung disease of unknown etiology and cure which leads
to rapid death within 2–3 years after diagnosis [56–61]. IPF is characterized by progressive and
irreversible destruction of the lung architecture caused by fibrotic “scar” formation that ultimately leads
to organ destruction and death from respiratory failure [62,63]. Its physiopathology remains poorly
characterized, although recent studies suggest that this disease results from aberrant dysregulated
wound healing response following chronic alveolar epithelial injury and aberrant proliferation of
fibroblasts [64]. In the presence of environmental stress, the amount of lung immune cell-derived
EVs increases dramatically, with an alteration of their composition (e.g., miRNAs). Several studies
have shown that these altered vesicles are responsible for part of the progression of inflammatory-
and fibrotic-related lung diseases. In an elegant study, Yao el al. have recently shown that M2
macrophage-derived exosomes overexpressing miR-328 contributed to enhanced pulmonary interstitial
fibroblast proliferation and promoted the progression of pulmonary fibrosis through the regulation
of FAM13A in a rat model [65]. Previously, we have identified 3 miRNAs showing an aberrant
expression in sputum-derived exosomes from IPF patients compared to healthy subjects (miR-142-3p,
miR-33a-5p, let-7d-5p) [25]. It could be interesting to study the impact of these miRNAs on IPF
progression (Figure 5).
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Figure 5. Role of lung EVs in the pathogenesis of Idiopathic Pulmonary Fibrosis (IPF). (1) In the
context of IPF, macrophage-derived EVs promote the progression of pulmonary fibrosis by delivering
miR-328 to pulmonary interstitial fibroblasts which enhances their proliferation [65]. (2) Altered levels
of three exosomal miRNAs (miR-142-3p, miR-33a-5p, let-7d-5p) in the sputum of IPF patients have
been reported [25]. These exosomal miRNAs could play a crucial role in the IPF progression.
Collectively, these studies reveal that exosomal miRNAs possess a detelerious effect in the context
of lung diseases. Their properties (pro-inflammatory or pro-fibrotic) depend on the disease type and
its stage, and allow them to promote the progression of lung diseases.
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5. Exosomes as Promising Diagnostic Biomarkers of Lung Diseases
A growing list of studies have showed that exosomes can be isolated from airway biofluids,
including BALF, saliva, and sputum [23–25,66]. The remarkable stability of exosomal content in the
bloodstream has been attributed to their encapsulation into a bilayer lipid membrane, which protects
them from the degrading enzymes (e.g., ribonucleases) present in the biofluids and protects them as
a potential biomarker. Accumulating studies have consistently reported the aberrant expression of
specific exosomal miRNAs in the blood or airway fluids during the course of lung disease progression,
such as COPD, asthma, or IPF (Table 2).
Table 2. EV miRNAs associated with lung diseases.


















































































Abbreviations: BALF, bronchoalveolar lavage fluid; COPD, chronic obstructive pulmonary disease; EVs, extracellular
vesicles; IPF, idiopathic pulmonary fibrosis; miRNAs, microRNAs; MVs, microvesicles.
For example, the plasma levels of several skeletal muscle-specific miRNAs (myo-miRNAs) (miR-1,
miR-499, miR-133, and miR-206) are elevated in patients with COPD compared to healthy controls [67].
Correlation of altered plasma myo-miRs with skeletal muscle function highlights the potential use
of this miRNA signature as biomarker of skeletal muscle dysfunction [67]. In a recent abstract,
Burke et al. have reported an alteration of the BALF levels of 23 exosomal miRNAs between COPD and
healthy ex-smokers, among those with miR-223-3p, miR-223-5p, miR-338-3p, miR-1469, miR-204-5p,
and miR-618 [66]. Interestingly, these differentially expressed exosomal miRNAs are associated to
relevant inflammatory pathways (TNFα, NF-κβ, and MAPK signaling) [66], suggesting their impact in
the persistent inflammatory response in COPD and therefore are potential targets for future therapies.
As for pulmonary fibrosis disease, we have identified recently 3 miRNAs dysregulated in sputum
exosomes from IPF patients compared to healthy subjects (miR-142-3p, miR-33a-5p, let-7d-5p) [25].
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Interestingly, we found a negative correlation between miR-142-3p and diffusing capacity of the lungs
for carbon monoxide/alveolar volume, suggesting that sputum exosomal miRNAs are associated with
the severity of lung fibrosis. This is the first characterization of miRNA content of sputum-derived
exosomes in IPF that identified promising biomarkers for diagnosis and disease severity.
In asthma, Maes et al. have also reported elevated levels of miR-142-3p and two other miRNAs,
miR-629-3p and miR-223-3p, in sputum of patients with severe asthma compared to healthy subjects [47].
Expression of miR-223-3p and miR-142-3p was associated with airway obstruction (FEV1/FVC). It would
be interesting to determine if altered miR-142-3p levels from asthma sputum were from exosomal
origins. Levänen et al. described an alteration of exosomal miR profile in BALF from asthmatic
patients compared to healthy subjects [24]. Significant differences in BALF exosomal miRNA were
detected for 24 miRNAs, including members of the let-7 and miRNA-200 families, providing robust
classification of patients with mild asymptomatic asthma from healthy subjects. In another study,
elevated levels of miR-128, miR-140-3p, miR-196b-5p, and miR-486-5p were measured in the serum
of severe asthmatics in comparison to healthy subjects [48]. Interestingly, the functional analysis of
altered miRNAs via mirPath software revealed that these miRNAs were associated to ErbB signaling
pathway, focal adhesion, and neurotrophin signaling pathway. In addition, several miRNAs associated
with immune modulation were identified in exosomes from asthmatic patients, including miR-24,
mir-27 [68], and miR-21 [44,45].
However, it is important to note the lack of overlap in the detection of altered exosomal miRNAs.
These variations are due in part to the different source biofluids (plasma/serum, BALF, sputum)
and technical issues involved in the detection of miRNAs, such as exosome isolation methods (size
exclusion chromatography, ultracentrifugation), RNA extraction methods, and miRNA screening
methods (small RNA sequencing, RT-qPCR array). Indeed, standardized protocols for isolation,
extraction, and quantification of exosomal miRNAs are desperately needed. Recently, the international
society of extracellular vesicles (ISEV) has provided guidelines for isolation methods and identification
of EVs, including exosomes [9,69], which should contribute on the identification of promising exosomal
miRNAs as diagnostic/prognostic biomarkers.
6. Exosomes as Promising Therapeutic Tools for Lung Diseases
6.1. Mesenchymal Stem Cell-Derived Exosomes Based Therapies
Exosomes derived from mesenchymal stem cells (MSCs) have been proposed as therapeutic
tools in many clinical disorders, including lung tissue repair and regeneration after ARDS.
Indeed, these vesicles present potential for tissue repair and wound healing [70], and anti-inflammatory
and immunosuppressive properties [71–74].
Several studies have highlighted the immunomodulatory effect of MSC-derived exosomes in
asthma. Recently, Du et al. have demonstrated that MSC-derived exosomes are able to upregulate
the release of immunosuppressive cytokines IL-10 and TGF-β1 from peripheral blood mononuclear
cells, thereby promoting proliferation and immune-suppression capacity of Tregs [75]. In addition,
Showalter et al. have established that MSC-derived exosomes are packaged with numerous metabolites
that have been directly associated with immunomodulation, including the polarization of M2
macrophages and the induction of regulatory T lymphocytes [76]. MSC-derived EVs also present a
protective effect in ALI. Zhu et al. demonstrated that human MSC-derived MVs were therapeutically
effective following E. coli endotoxin-induced ALI in mice, in part through the expression of Keratinocyte
Growth Factor mRNA in the injured alveoli [73]. MVs were able to block inflammation by reducing
the influx of neutrophils (73%) and macrophage inflammatory protein-2 levels (49%) in the BALF.
In a pig model of influenza virus, Khatri et al. recently demonstrated that MSC-derived EVs
possess anti-influenza and anti-inflammatory properties [77]. Indeed, intratracheal administration of
MSC-derived EVs 12 h after influenza virus infection significantly reduced virus shedding in the nasal
swabs, influenza virus replication in the lungs, and virus-induced production of pro-inflammatory
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cytokines in the lungs of infected pigs [77]. MSC-derived exosomes from adipose tissue are also able to
reduce pathological symptoms in an atopic-dermatitis mouse model and mRNA expression of various
inflammatory cytokines (such as IL-4, IL-23, IL-31, and tumor necrosis factor-α) [78].
6.2. Exosomes as Natural Drug-Delivery Vehicles
The exploitation of exosomes as drug delivery vehicles offers important advantages compared to
other nanoparticulate drug delivery systems, such as liposomes and polymeric nanoparticles [79,80].
Exosomes have a long circulating half-life, the intrinsic ability to target tissues, biocompatibility,
and minimal or no inherent toxicity issues [81,82]. Due to their biological properties, exosomes
have been proposed as drug- and vaccine-delivery vesicles. For example, plant-derived molecules,
such as celastrol and curcumin, are endowed with in vitro antioxidant, immunomodulatory,
anti-inflammatory, and anticancer effects, but have a poor solubility. Several groups have investigated
the incorporation of these molecules into exosomes, which increases their solubility, their stability,
and their bioavailability [83–85], and a phase I study is ongoing to investigate the ability of exosomes
to deliver curcumin to normal and colon cancer tissue (NCT01294072). In addition, exosomes are
efficient biovectors for small RNAs therapies because they are natural vectors of molecular cargoes
(e.g., pre-miRNAs, miRNAs) and are able to deliver it to target cells under different pathophysiological
contexts [86–88]. For example, the study of Ohno et al. was one of the earliest proof-of-concept studies
demonstrating that exosomes from human embryonic kidney cells could efficiently deliver exogenous
therapeutic let-7a in an EGFR-expressing xenograft breast cancer tissue in RAG2(-/-) mice and induce
tumor regression [89].
7. Concluding Remarks and Future Perspectives
Interest in the impact of lung exosomes in the modulation of lung homeostasis, as well as their
contribution in the progression of a variety of lung diseases, has grown substantially over the past
few years. The identification of altered exosomal miRNAs in a lung disease context, as well as
the elucidation of their role in the pathogenesis of lung diseases, have provided novel diagnostic
biomarkers and therapeutic targets. It is important to mention that the interpretation of biological
function of individual altered miRNAs is difficult because miRNAs work together and generally have
small individual effects upon gene expression.
Before using these in clinics, several major issues need to be resolved. In order to use exosomal
miRNAs as diagnostic/prognostic biomarkers, the protocols for exosome isolation need to be optimized
and standardized to minimize the variations due to technical issues. As the effect of miRNAs is
fundamentally dependent upon the mRNAs present within the target cell, it is critical to identify the
cellular destination of lung exosomes in order to interpret the biological function of exosomal miRNAs.
Further investigations need to be performed to identify target cells. Concerning the development
of miRNA-based therapies, further investigations need to be performed to improve the delivery of
therapeutic miRNAs in specific organs, as well as specific cells, such as alveolar ECs or alveolar
macrophages, which play a critical role in the development of lung diseases. We (and others) have
begun to explore the use of exosomes loaded with protective cargoes (anti-inflammatory/anti-fibrotic
miRNAs) for therapeutic issues.
However, what remains unclear and needs careful investigation is the long-term effect of miRNA
mimics/anti-miRNAs since they can persist in the tissues for several months [90] and induce toxicity.
Furthermore, one miRNA can target directly several molecular pathways and therefore could induce
unintended effects.
Future research will elucidate more deeply the role of exosomes/exosomal miRNAs in the
pathogenesis of lung diseases and provide additional information to develop new diagnostics and
therapeutics for lung diseases.
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